Feb. 12, 2026 8:30 AM ETProfound Medical Corp. (PROF), PRN:CA “We are deeply grateful to INOVAIT for supporting a vision where AI‑enabled, image‑guided therapies like TULSA-PRO are not only developed ...
A phase 2 randomized, double-blind trial tested oxybutynin 2.5 mg BID and 5 mg BID versus placebo for six weeks in men on stable ADT with ≥28 weekly hot flashes. Dose-dependent efficacy was observed, ...
TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage innovator in interventional MRI (“iMRI”) procedures, is ...
In a Phase III randomized trial, Mass General Brigham researchers found that stereotactic radiation targeting individual tumors led to lower symptom burden, better cognitive outcomes, and better ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果